ID   Kasumi-1
AC   CVCL_0589
SY   KASUMI-1; Kasumi 1; KASUMI1; Kasumi1
DR   BTO; BTO:0004136
DR   CLO; CLO_0007068
DR   CLO; CLO_0007069
DR   EFO; EFO_0006607
DR   MCCL; MCC:0000264
DR   CLDB; cl2998
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2724
DR   BCRC; 60505
DR   BCRJ; 0305
DR   BioGRID_ORCS_Cell_line; 1617
DR   BioSample; SAMN01821572
DR   BioSample; SAMN01821642
DR   BioSample; SAMN01821688
DR   BioSample; SAMN03473161
DR   BioSample; SAMN10988020
DR   cancercelllines; CVCL_0589
DR   CCRID; 3101HUMSCSP5015
DR   CCRID; 3101HUMTCHu202
DR   CCRID; 4201HUM-CCTCC00296
DR   CCTCC; GDC0296
DR   Cell_Model_Passport; SIDM01005
DR   ChEMBL-Cells; CHEMBL3307835
DR   ChEMBL-Targets; CHEMBL613988
DR   CLS; 300226
DR   Cosmic; 787441
DR   Cosmic; 907275
DR   Cosmic; 975258
DR   Cosmic; 981579
DR   Cosmic; 987968
DR   Cosmic; 1012076
DR   Cosmic; 1078725
DR   Cosmic; 1149336
DR   Cosmic; 1181600
DR   Cosmic; 1451847
DR   Cosmic; 1476423
DR   Cosmic; 1509202
DR   Cosmic; 1516633
DR   Cosmic; 1524831
DR   Cosmic; 1623636
DR   Cosmic; 1779131
DR   Cosmic; 2089650
DR   Cosmic; 2131540
DR   Cosmic; 2306211
DR   Cosmic; 2690663
DR   Cosmic; 2701742
DR   Cosmic; 2750859
DR   Cosmic-CLP; 907275
DR   DepMap; ACH-000263
DR   DSMZ; ACC-220
DR   DSMZCellDive; ACC-220
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 907275
DR   GEO; GSM236785
DR   GEO; GSM236821
DR   GEO; GSM482490
DR   GEO; GSM506744
DR   GEO; GSM506867
DR   GEO; GSM506973
DR   GEO; GSM743409
DR   GEO; GSM887197
DR   GEO; GSM888270
DR   GEO; GSM955189
DR   GEO; GSM955190
DR   GEO; GSM955191
DR   GEO; GSM1374590
DR   GEO; GSM1446745
DR   GEO; GSM1669979
DR   GEO; GSM2716744
DR   GEO; GSM2716745
DR   GEO; GSM2716746
DR   GEO; GSM2716747
DR   GEO; GSM4254129
DR   IARC_TP53; 21428
DR   IZSLER; BS TCL 242
DR   JCRB; JCRB1003
DR   JCRB; NIHS0235
DR   LiGeA; CCLE_291
DR   LINCS_LDP; LCL-1055
DR   PharmacoDB; KASUMI1_733_2019
DR   PRIDE; PXD000185
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0589
DR   PubChem_Cell_line; CVCL_0589
DR   Wikidata; Q38098914
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2018839;
RX   PubMed=8558913;
RX   PubMed=9738977;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=11753612;
RX   PubMed=12111653;
RX   PubMed=15621809;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=16523483;
RX   PubMed=18292219;
RX   PubMed=18385756;
RX   PubMed=20164919;
RX   PubMed=20227111;
RX   PubMed=20922763;
RX   PubMed=22068913;
RX   PubMed=22460905;
RX   PubMed=23955599;
RX   PubMed=24211243;
RX   PubMed=24976338;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28109323;
RX   PubMed=28196595;
RX   PubMed=29491412;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=32180206;
RX   PubMed=35839778;
WW   http://www.cccells.org/cellreqs-ncipptp.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Japanese.
CC   Doubling time: 40-45 hours (PubMed=2018839); 40 hours (PubMed=25984343); 53 hours (PubMed=20922763); ~48-72 hours (DSMZ=ACC-220).
CC   HLA typing: A*26:01,26:01; B*40:06,40:06; C*03:03,08:01 (PubMed=26589293).
CC   HLA typing: A*26:02:01,26:01:01; B*40:06:01,48:01:01; C*03:03:01,08:01:01; DPB1*02:01:02,02:01:02; DRA*01:01:01,01:01:01; DRB1*14:54:01,09:01:02 (DSMZCellDive=ACC-220).
CC   Karyotypic information: Has lost chromosome Y (PubMed=2018839).
CC   Karyotypic information: Some chromosome Y fragments are integrated into other chromosomes (PubMed=18292219).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1535; RUNX1T1; Name(s)=RUNX1-RUNX1T1, AML1-ETO (PubMed=11753612; PubMed=15843827; PubMed=24976338; PubMed=25485619).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Heterozygous (PubMed=12111653; PubMed=18385756).
CC   Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Lys330Profs*6 (c.987insCCGG); Zygosity=Unspecified (PubMed=23955599).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.19%; Native American=0%; East Asian, North=74.84%; East Asian, South=22.29%; South Asian=0%; European, North=0%; European, South=1.67% (PubMed=30894373).
CC   Misspelling: Kusami-1; Cosmic=1516633; Cosmic=1623636; Cosmic=2750859.
CC   Misspelling: KUSAMI-1; Cosmic=2306211.
CC   Discontinued: JCRB; NIHS0235; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC; CLS; Cosmic-CLP; COG; DSMZ; Genomics_Center_BCF_Technion; JCRB; PubMed=20922763; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D10S1248: 13,15
ST   D12S391: 20
ST   D13S317: 11,13
ST   D16S539: 9,12
ST   D18S51: 15,16
ST   D19S433: 13,15.2 (COG; Genomics_Center_BCF_Technion; PubMed=20922763)
ST   D19S433: 13,16 (DSMZ)
ST   D1S1656: 14,16
ST   D21S11: 30,31
ST   D22S1045: 17
ST   D2S1338: 19
ST   D2S441: 11,14
ST   D3S1358: 15,17
ST   D5S818: 9,11
ST   D7S820: 8,11
ST   D8S1179: 13,14
ST   FGA: 22,24
ST   Penta D: 12
ST   Penta E: 11
ST   TH01: 6,9
ST   TPOX: 8,9
ST   vWA: 14 (ATCC; CLS; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; JCRB; PubMed=20922763; PubMed=25877200)
ST   vWA: 14,18 (COG)
DI   NCIt; C9381; Childhood acute myeloid leukemia with maturation
DI   ORDO; Orphanet_98834; Acute myeloblastic leukemia with maturation
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 47
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2018839; DOI=10.1182/blood.V77.9.2031.2031;
RA   Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N.;
RT   "Establishment of a human acute myeloid leukemia cell line (Kasumi-1)
RT   with 8;21 chromosome translocation.";
RL   Blood 77:2031-2036(1991).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=11753612; DOI=10.1038/sj.leu.2402318;
RA   Xiao Z., Greaves M.F., Buffler P., Smith M.T., Segal M.R., Dicks B.M.,
RA   Wiencke J.K., Wiemels J.L.;
RT   "Molecular characterization of genomic AML1-ETO fusions in childhood
RT   leukemia.";
RL   Leukemia 15:1906-1913(2001).
//
RX   PubMed=12111653; DOI=10.1038/sj.thj.6200168;
RA   Beghini A., Magnani I., Ripamonti C.B., Larizza L.;
RT   "Amplification of a novel c-Kit activating mutation Asn(822)-Lys in
RT   the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid
RT   leukemia.";
RL   Hematol. J. 3:157-163(2002).
//
RX   PubMed=15621809; DOI=10.1080/10428190400007565;
RA   Larizza L., Magnani I., Beghini A.;
RT   "The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid
RT   leukemia.";
RL   Leuk. Lymphoma 46:247-255(2005).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=16523483; DOI=10.1002/gcc.20317;
RA   Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H.,
RA   Dexter T.J., Ashworth A., Kearney L.;
RT   "Array CGH of fusion gene-positive leukemia-derived cell lines reveals
RT   cryptic regions of genomic gain and loss.";
RL   Genes Chromosomes Cancer 45:554-564(2006).
//
RX   PubMed=18292219; DOI=10.1101/gr.068304.107;
RA   Chen J., Kim Y.C., Jung Y.-C., Xuan Z.-Y., Dworkin G., Zhang Y.-M.,
RA   Zhang M.Q., Wang S.M.;
RT   "Scanning the human genome at kilobase resolution.";
RL   Genome Res. 18:751-762(2008).
//
RX   PubMed=18385756; DOI=10.1038/leu.2008.61;
RA   Becker H., Pfeifer D., Afonso J.D., Nimer S.D., Veelken H.,
RA   Schwabe M., Lubbert M.;
RT   "Two cell lines of t(8;21) acute myeloid leukemia with activating KIT
RT   exon 17 mutation: models for the 'second hit' hypothesis.";
RL   Leukemia 22:1792-1794(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20227111; DOI=10.1016/j.leukres.2010.02.012;
RA   Pedranzini L., Mottadelli F., Ronzoni S., Rossella F., Ferracin M.,
RA   Magnani I., Roversi G., Colapietro P., Negrini M., Pelicci P.G.,
RA   Larizza L.;
RT   "Differential cytogenomics and miRNA signature of the acute myeloid
RT   leukaemia Kasumi-1 cell line CD34+38- compartment.";
RL   Leuk. Res. 34:1287-1295(2010).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=24211243; DOI=10.1016/j.exphem.2013.10.006;
RA   Herrmann M.D., Lennerz J.K., Bullinger L., Bartholomae S.,
RA   Holzmann K., Westhoff M.-A., Corbacioglu S., Debatin K.-M.;
RT   "Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute
RT   myeloid leukemia cells correlate with altered KIT expression.";
RL   Exp. Hematol. 42:90-100(2014).
//
RX   PubMed=24976338; DOI=10.1016/j.leukres.2014.06.002;
RA   Migas A.A., Mishkova O.A., Ramanouskaya T.V., Ilyushonak I.M.,
RA   Aleinikova O.V., Grinev V.V.;
RT   "RUNX1T1/MTG8/ETO gene expression status in human
RT   t(8;21)(q22;q22)-positive acute myeloid leukemia cells.";
RL   Leuk. Res. 38:1102-1110(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28109323; DOI=10.1186/s13045-017-0396-0;
RA   Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A.,
RA   Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M.,
RA   Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.;
RT   "Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion
RT   gene.";
RL   J. Hematol. Oncol. 10:26.1-26.5(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29491412; DOI=10.1038/s41388-018-0150-2;
RA   Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D.,
RA   Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N.,
RA   Gerstberger T., Zuber J., Savarese F., Kraut N.;
RT   "The novel BET bromodomain inhibitor BI 894999 represses
RT   super-enhancer-associated transcription and synergizes with CDK9
RT   inhibition in AML.";
RL   Oncogene 37:2687-2701(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32180206; DOI=10.1007/s13577-020-00347-5;
RA   Kasai F., Asou H., Ozawa M., Kobayashi K., Kuramitsu H., Satoh M.,
RA   Kohara A., Kaneko Y., Kawamura M.;
RT   "Kasumi leukemia cell lines: characterization of tumor genomes with
RT   ethnic origin and scales of genomic alterations.";
RL   Hum. Cell 33:868-876(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//